These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20559037)

  • 1. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy.
    Søgaard OS; Schønheyder HC; Bukh AR; Harboe ZB; Rasmussen TA; Ostergaard L; Lohse N
    AIDS; 2010 Jun; 24(9):1315-22. PubMed ID: 20559037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
    Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
    Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
    Falcó V; Jordano Q; Cruz MJ; Len O; Ribera E; Campins M; Crespo M; Ocaña I; Rodrigo MJ; Pahissa A
    Vaccine; 2006 Mar; 24(14):2567-74. PubMed ID: 16423429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
    HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opsonic function of bronchoalveolar lavage IgG after pneumococcal vaccination in HIV-infected and uninfected adults.
    Tam JC; Grant NL; Freire-Moran L; Tolmie H; French N; Gordon SB
    J Allergy Clin Immunol; 2009 Jun; 123(6):1420-1. PubMed ID: 19423153
    [No Abstract]   [Full Text] [Related]  

  • 8. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine.
    Rodriguez-Barradas MC; Alexandraki I; Nazir T; Foltzer M; Musher DM; Brown S; Thornby J
    Clin Infect Dis; 2003 Aug; 37(3):438-47. PubMed ID: 12884170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
    Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
    Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
    Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
    AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
    Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
    Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy.
    Lu CL; Chang SY; Sun HY; Liu WC; Tseng YT; Hsieh CY; Wu CH; Hung CC; Chang SC
    J Formos Med Assoc; 2012 Aug; 111(8):445-51. PubMed ID: 22939663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
    Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
    Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
    Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
    J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.
    Chen M; Ssali F; Mulungi M; Awio P; Yoshimine H; Kuroki R; Furumoto A; Tanimura S; Kityo C; Nagatake T; Mugyenyi P; Oishi K
    Vaccine; 2008 Sep; 26(38):4962-8. PubMed ID: 18639599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy.
    Subramaniam KS; Segal R; Lyles RH; Rodriguez-Barradas MC; Pirofski LA
    J Infect Dis; 2003 Mar; 187(5):758-68. PubMed ID: 12599049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy.
    D'Orsogna LJ; Krueger RG; McKinnon EJ; French MA
    AIDS; 2007 Aug; 21(13):1747-52. PubMed ID: 17690573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses.
    Tasker SA; Wallace MR; Rubins JB; Paxton WB; O'Brien J; Janoff EN
    Clin Infect Dis; 2002 Mar; 34(6):813-21. PubMed ID: 11850863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.